PLEASE JOIN US FOR

INDUSTRY SYMPOSIUM

OPTIMIZING TESTING AND TREATMENT STRATEGIES IN THE ERA OF PRECISION MEDICINE:

NTRK gene fusion and RET alteration cases from the clinic

An expert panel case-based discussion

PROGRAM OBJECTIVES

  • Learn about the importance of comprehensive genomic testing in NSCLC and thyroid cancers to inform optimal treatment decisions for patients
  • Understand from a case-based panel discussion the practical considerations for optimal testing approaches in the detection of NTRK gene fusions and RET alterations in NSCLC and thyroid cancers

FACULTY

  • Rachel Butler MBE
    Professor, Head of Bristol Genetics Lab and Operational Director for SW Genomics Laboratory, UK
  • Alexander Drilon MD
    Chief, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, US
  • Rossella Elisei MD
    Professor, University of Pisa, Endocrine Unit, Department of Clinical and Experimental Medicine, Italy
  • Michelle Williams MD
    Professor, Section Chief Head & Neck Pathology, Division of Pathology-Lab Medicine, University of Texas,
    MD Anderson Cancer Center, USA

29 AUGUST 2021

11:45—13:15 CET

JOIN EVENT

©7/2021 Bayer.

All rights reserved.

PP-VIT-ALL-0433-1

©7/2021 Illumina.

All rights reserved.

©7/2021 Lilly.

All rights reserved.

GM-22306